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Abstract
Background: Cardiac metastasis from colorectal cancer is rare. There is little evidence supporting the effectiveness
of chemotherapy, and standard therapy for metastatic cardiac tumors has not been established.
Case presentation: A 76-year-old woman presented with a right ventricle tumor that was detected incidentally on
screening cardiac ultrasonography. The initial computed tomography (CT) scan showed the cardiac tumor, which
was approximately 40 mm in size, and multiple pulmonary nodules. Serum levels of tumor markers CEA and CA19-9
were elevated aberrantly. The suspected primary tumor, a well-differentiated adenocarcinoma of the transverse
colon with wild-type KRAS was found by colonoscopy, and treatment with 5-fluorouracil, leucovorin, and oxaliplatin
(modified FOLFOX6) plus panitumumab was initiated. After 4 courses of the therapy, a CT scan showed that the
cardiac tumor size had markedly decreased and the pulmonary nodules had diminished. The serum levels of CEA
and CA19-9 were also markedly decreased. After 12 courses of chemotherapy during 10 months of treatment, the
patient continued to show a partial response, and she remained asymptomatic with continuation of the treatment
through 15 courses.
Conclusion: To the best of our knowledge, this is the first report of the efficacy of combination therapy using
cytotoxic and molecular targeted agents against cardiac metastasis from colon cancer.
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Background
Colorectal cancer (CRC) is one of the three most
commonly diagnosed malignancies worldwide, and it is a
leading cause of death due to cancer [1]. The common
sites of metastases from CRC are the lymph nodes, liver,
and lungs. Autopsy studies have shown that the incidence
of cardiac metastasis from CRC is 1.4 to 7.2% [2–4]. To
date, however, only 12 cases of cardiac metastases from
CRC have been reported in the English literature [5–7].
The prognosis for patients with metastatic cardiac tumors
is poor, and chemotherapy alone against cardiac metasta-
sis from CRC has rarely been effective [8]. Recently, anti-
epidermal growth factor receptor (EGFR) monoclonal
antibodies such as cetuximab or panitumumab have
provided clinical benefit in patients with KRAS wild-
type CRC [9, 10]. We herein present a case of cardiac
metastasis from CRC that showed an appreciable re-
sponse to combination therapy with oxaliplatin-based
chemotherapy and panitumumab.
Case presentation
A 76-year-old woman who was incidentally diagnosed
with a tumor of the right ventricle by screening cardiac
ultrasonography was referred to our hospital for further
examination. Chest computed tomography (CT) showed
the cardiac tumor, which was approximately 40 mm in
size (Fig. 1a), and multiple pulmonary nodules. The
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patient had elevated serum tumor markers (CEA, 724
ng/mL; and CA19-9, 54 U/mL), and positron emission
tomography-computed tomography (PET-CT) showed
abnormal uptake of fluorodeoxyglucose in the cardiac
mass, the pulmonary nodules, and the transverse colon
(Fig. 1b and c). Colonoscopy confirmed a 25-mm type 2
tumor in the transverse colon, which was diagnosed as a
well-differentiated adenocarcinoma with wild-type KRAS
on histopathological examination (Fig. 1d and e). With re-
gard to the cardiac tumor, dynamic magnetic resonance
imaging (MRI) showed an irregular 54- × 32- × 31-mm
mass that was nearly isointense to the intact myocardium
on both T1-weighted and T2-weighted images and was
characterized by a ring enhancement (Fig. 1f and g). The
tumor was lateral to the outflow tract of the right ventricle
(Fig 1h), fixed to the endocardium, and infiltrated the
myocardium. Tissue biopsy was considered unsafe be-
cause of the location of the tumor. There were no electro-
cardiographic abnormalities, and there was no sign of
systolic or diastolic dysfunction on the echocardiogram.
Fig. 1 Initial diagnostic evaluation. Pre-treatment computed tomography (CT) scan showing the cardiac tumor (a). Positron emission
tomography-computed tomography (PET-CT) scan showing abnormal uptake of fluorodeoxyglucose in the right ventricular mass (SUV max; 5.4)
(b) and the transverse colon (SUV max; 4.4) (c). Endoscopic view of the primary lesion in the transverse colon (d) and the biopsy specimen
showing well-differentiated adenocarcinoma (e). Cardiac magnetic resonance imaging (MRI; T1-weighted image, sagittal view) showing the
irregular 54 × 32 mm mass, which had nearly equal intensity to the intact myocardium (f). The tumor is heterogeneous and characterized by a
ring enhancement (g). MRI (long-axis view of the right ventricle) showing the tumor location lateral to the outflow tract of the right ventricle (h)
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The left ventricular ejection fraction was 69%, and the
Doppler studies showed normal blood flow that was
unobstructed by the tumor. The tumor was deemed inop-
erable by cardiovascular surgeons because of the myocar-
dial invasion. Thus, based on imaging study findings, we
diagnosed the heart and lung lesions as cardiac and
pulmonary metastases from the primary colon cancer
(UICC cT2N0M1b Stage IVb).
The patient was treated with a modified 5-fluorouracil
(400 mg/m2 bolus then 2400 mg/m2 46-h infusion),
leucovorin (200 mg/m2), and oxaliplatin (85 mg/m2)
(mFOLFOX6) regimen plus panitumumab (6 mg/kg)
every 2 to 3 weeks. A follow-up CT after 4 courses of
chemotherapy showed that the cardiac tumor size de-
creased from 40 to 26 mm in size (Fig. 2a) and the mul-
tiple pulmonary nodules were also diminished. The
serum CEA and CA19-9 levels were markedly decreased,
from 724 to 29 ng/mL and 54 to 10 U/mL, respectively.
The patient tolerated the treatment well. The most se-
vere toxicity according to the common terminology
criteria for adverse events (CTCAE, version 4.0) was
grade 2 neuropathy that emerged after 6 courses of
chemotherapy and was associated with the oxaliplatin. A
follow-up MRI after 8 courses of chemotherapy indi-
cated that the patient had sustained a prolonged signifi-
cant response (Fig. 2b). Oxaliplatin was discontinued
after 10 courses of chemotherapy due to neuropathy.
The dosage of chemotherapy was also reduced (5-fluoro-
uracil [320 mg/m2 bolus then 1920 mg/m2 46-h infusion],
leucovorin [200 mg/m2], and panitumumab [4.8 mg/kg]
every 3 or 4 weeks). The patient remained asymptomatic
with a prolonged partial response 10 months (12 courses
of chemotherapy) after initial treatment (Fig. 2c). How-
ever, a follow-up CT after 15 courses of chemotherapy
indicated progressive disease. The primary CRC remained
undetectable by CT, but the cardiac tumor increased to 31
mm in size. Both the serum CEA and CA19-9 levels
continued to increase. Despite our recommendation for
further treatment by a second-line regimen, the patient
elected to receive only best supportive care. Currently, the
patient is alive over 2 years after the diagnosis of the
cardiac metastasis.
Discussion and conclusions
Cardiac metastasis from CRC is rare. A progressive
metastatic mass of the heart occasionally causes acute
heart failure or superior vena cava syndrome, resulting
in sudden death [7, 11, 12]. Because the incidence of
cardiac metastases was reported to be 1.4 to 7.2% in
autopsy studies, echocardiography or cardiac MRI may
not be necessary for all CRC patients. However, echocar-
diography should be performed if advanced CRC
patients exhibit any sign of heart disease.
MRI is considered useful for the diagnosis of cardiac
tumors [13]. It can accurately recognize the pericardium,
the myocardial walls, and the cardiac chambers, thereby
allowing for evaluation of infiltration or extension of the
tumor. Additionally, reference to the known distinctive
appearance is useful for the differential diagnosis [14].
For example, angiosarcoma, which is one of the most
Fig. 2 Therapeutic response. A follow-up computed tomography (CT) scan showing the smaller cardiac tumor after 3 months and 4 courses of
chemotherapy] (a). A follow-up magnetic resonance imaging (MRI) after 8 courses of chemotherapy also shows a sustained reduction in the
tumor size (b). CT after 10 months and 12 courses of chemotherapy (c)
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common subtypes of sarcomas, has marked signal het-
erogeneity on T1- and T2-weighed images with hyperin-
tense foci corresponding to intratumoral hemorrhage
[15], and the feature of ring enhancement of a lesion,
which we observed in the present case has also been
documented in previous cases of cardiac metastasis from
CRC [5, 6]. Thus, this finding seems valuable in the
diagnosis of a secondary malignant cardiac tumor.
Concerning the treatment of cardiac metastasis, sev-
eral reports emphasize the role of surgery based on
significant improvement in survival times [16], and sur-
gical resection for liver and pulmonary metastasis is now
generally accepted and performed as a potentially cura-
tive treatment [17, 18]. However, the potential survival
benefit from cardiac surgery may be counterbalanced by
perioperative morbidity and mortality. Therefore, indica-
tions for surgery in patients with metastatic cardiac
tumors must be carefully considered, particularly for
asymptomatic elderly patients or those with other meta-
static lesions, such as in this case.
Recently, anti-EGFR monoclonal antibodies (cetuximab
or panitumumab) have become widely used and have
improved the prognosis for patients with wild-type RAS
metastatic CRC. Oxaliplatin-based chemotherapy plus
panitumumab showed higher response rates compared to
oxaliplatin-based chemotherapy alone, especially in
achieving early tumor shrinkage, which is associated with
improved progression-free survival and overall survival
[19]. In clinical practice, we routinely performed only
KRAS mutational analysis because of a lack of health
insurance coverage. However, an extended RAS analysis
was considered essential for this case; therefore, we
conducted an analysis of banked patient tumor specimens,
which revealed that the tumor had wild-type KRAS exon 2
(codons 12, 13), exon 3 (codons 59, 61), exon 4 (codons
117, 146) and NRAS exon 2 (codons 12, 13), exon 3
(codons 59, 61), and exon 4 (codons 117, 146). During the
past decade, molecular targeted therapy has provided a
promising strategy for clinical oncology, and metastatic
cardiac tumors originating from renal cell carcinomas
have been successfully treated with tyrosine kinase inhibi-
tors (sunitinib or pazopanib) [20, 21]. However, we believe
that ours is the first report of significant reduction of a
metastatic cardiac tumor from a CRC by the use of
molecular targeted agents.
It must be noted that the possibility of a primary
cardiac tumor in the present case cannot be denied
completely because the diagnosis of metastatic CRC
could not be confirmed by biopsy. We treated the
cardiac tumor as metastasis from CRC for the following
reasons. First, primary tumors of the heart are mostly
myxomas. In our patient, the abnormal uptake of fluoro-
deoxyglucose on the CT-PET scan strongly indicated a
malignancy. Next, primary malignant tumors of the
heart, such as sarcomas, lymphoma, and mesothelioma,
are generally less common than metastases [22], and
primary cardiac tumors are known to have the most
unfavorable prognosis, as they are rapidly-growing and
extremely refractory to chemotherapy [23]. In our pa-
tient, the response to chemotherapy, i.e., the tumor
shrinkage and the decrease in the serum levels of tumor
markers, supported the diagnosis of a metastatic cardiac
tumor and indicated that the combination of cytotoxic
and molecular targeted chemotherapy may be a suitable
treatment for select patients with asymptomatic cardiac
CRC metastases.
In conclusion, we encountered a patient who had a
cardiac metastasis from CRC that responded well to
oxaliplatin-based chemotherapy plus panitumumab. This
indicates that the combination of cytotoxic and molecu-
lar targeted chemotherapy may be suitable for select
patients with asymptomatic metastatic cardiac tumors.
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